CDP-Choline
Citicoline
CDP-Choline (Citicoline) is a cognitive & mood research compound. Delivers choline plus cytidine/uridine — supports acetylcholine and membrane phospholipid synthesis for cognition.
CDP-Choline quick facts
| Reported research dose | 200mg-600mg |
| Route | Oral |
| Frequency | 1-2x Daily · 5 On 2 Off or Daily |
| Half-life | Long (biphasic) |
| Forms | Oral |
| Evidence level | Human trials |
The better-studied choline for cognition. Smooth, no crash.
How CDP-Choline works
Delivers choline plus cytidine/uridine — supports acetylcholine and membrane phospholipid synthesis for cognition.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get CDP-Choline
Buy CDP-Choline at RUPharma →The evidence for CDP-Choline
Graded by what exists behind each claim.
✅ Clinically validated
- A genuinely well-evidenced compound. Citicoline is a prescription medicine in Europe and Japan for stroke and cognitive impairment, with numerous randomized trials. A Cochrane review of citicoline in cognitive impairment from cerebrovascular disease found evidence of benefit on memory and behavior.
- Trials in stroke recovery have been mixed — the large ICTUS trial was neutral — but the cognitive-impairment literature is more consistent.
📊 Correlative data
- Very wide use, including as a stimulant-free focus aid and as the choline source paired with racetams. Excellent tolerability record across decades.
🧪 Theoretical / extrapolated
- Cytidine diphosphate-choline. It is cleaved into cytidine and choline, both of which cross the blood-brain barrier — the cytidine becoming uridine, which supports phosphatidylcholine synthesis for cell membranes.
- Supplying membrane precursors rather than only a neurotransmitter substrate is the mechanistic case for it over plain choline, and it predicts a structural effect building over weeks rather than an acute one.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What CDP-Choline actually does
CDP-choline is not a drug that acts on a receptor. It is an intermediate you are trying to make more of. Phosphatidylcholine — the dominant phospholipid of every neuronal membrane — is built by the Kennedy pathway in three steps: choline is phosphorylated by choline kinase, phosphocholine is joined to CTP by CTP:phosphocholine cytidylyltransferase to make CDP-choline, and CDP-choline then donates its phosphocholine head group to diacylglycerol. The middle step is the rate-limiting one, which is exactly why supplying its product looks like such an obvious idea.
Except that swallowing CDP-choline does not deliver CDP-choline. Following oral or parenteral administration, citicoline releases its two components, cytidine and choline, and it is those that circulate; absorption by the oral route is virtually complete, so oral bioavailability is approximately the same as intravenous Secades 2006. The intact dinucleotide is taken apart before it reaches the circulation and reassembled inside cells. That is not a flaw in the product — it is how it works — but it means every claim about ‘delivering CDP-choline to the brain’ is describing something that does not happen.
And here is the finding that reorganizes the whole page. Wurtman 2000 gave twelve fasting subjects oral CDP-choline at 500, 2,000 and 4,000 mg and sampled plasma eleven times over twelve hours. Plasma choline rose dose-dependently and stayed significantly elevated for 5, 8 and 10 hours respectively. Plasma uridine rose 70–90% after 500 mg and 100–120% after 2,000 mg. And plasma cytidine was not reliably detectable — below 100 nanomolar — at any dose. The authors' own conclusion: the circulating substrates through which oral citicoline increases brain membrane phosphatide synthesis in humans are uridine and choline, and not cytidine and choline as in rats.
Why that happens, and why it matters more than anything else here. Humans carry high cytidine deaminase activity; cytidine is converted to uridine almost as fast as it appears. Uridine then enters the cell, is phosphorylated to UTP, and is aminated to CTP — the same paper showed uridine converted directly to CTP in PC-12 cells. So the pyrimidine arm of the pathway is supplied, just by a different molecule than the rodent literature describes. Every rodent study of citicoline that attributes its effect to cytidine is describing a route humans barely use.
There is a ceiling, and it is measurable. Raising the dose from 2,000 to 4,000 mg produced no further increase in plasma uridine Wurtman 2000. A saturable step — transport, or deamination capacity — caps the pyrimidine arm somewhere around 2 g. The choline arm kept climbing. So above about 2 g you are buying more choline and no more uridine, which is a different product than the one you started with.
Cell, rodent, human — and where it stops
In cells. Uridine converted directly to CTP in PC-12 neuron-derived cells Wurtman 2000; and a large preclinical literature on membrane phospholipid synthesis, restoration of mitochondrial and Na+/K+ ATPase activity, inhibition of phospholipase activation, reduced apoptosis and raised norepinephrine and dopamine Secades 2006.
In rodents: extensive, and built on the wrong metabolite. The animal pharmacology is real and reproducible — smaller ischemic lesion volume, faster resolution of cerebral edema, better learning in aged animals Secades 2006. But rats deliver the pyrimidine as cytidine and humans deliver it as uridine Wurtman 2000, so the mechanistic step the rodent papers describe is not the step that occurs in a person. The phenotype may still transfer; the explanation does not.
In humans, acute stroke: negative, at scale. The ICTUS trial was an international, randomized, multicenter, placebo-controlled study of citicoline in acute ischemic stroke Davalos 2012. It is the largest and best-designed test the compound has ever had, and it did not show benefit.
In humans, traumatic brain injury: negative, at scale. The Citicoline Brain Injury Treatment Trial (COBRIT) tested citicoline on functional and cognitive status after traumatic brain injury and did not find an improvement Zafonte 2012.
The obstacle, stated without softening. The two largest, most rigorous human trials of this compound — in acute stroke and in head injury — were both negative on their primary endpoints. The favorable human literature is older, smaller, mostly European, and concentrated in chronic cognitive impairment of vascular origin rather than acute injury Secades 2006. Those are different clinical questions on different timescales, and the honest reading is that citicoline failed as a neuroprotectant in acute brain injury while the chronic cognitive question remains genuinely open. Neither of those populations is a healthy adult taking 300 mg for focus, and there is no large trial in that group at all.
CDP-Choline pharmacokinetics — how much of it actually gets in
Oral absorption is essentially complete, and oral bioavailability is approximately equal to intravenous Secades 2006. For a polar dinucleotide that sounds impossible, and the resolution is that the molecule is not absorbed as such: it is hydrolyzed to choline and cytidine, both of which are ordinary nutrients with dedicated transporters, and reassembled intracellularly. The oral barrier is therefore not a barrier at all, and the intravenous form offers no pharmacokinetic advantage — only a faster onset.
The exposure window, with numbers. Plasma choline stays significantly elevated for 5 hours after 500 mg, 8 hours after 2,000 mg and 10 hours after 4,000 mg; plasma uridine is elevated for 5 to 6 hours at every dose Wurtman 2000. That is the real half-life question answered. The “long, biphasic” half-life quoted for citicoline comes from radiolabel studies that follow the two components through general metabolism after they have stopped being a drug; the pharmacologically useful window is the five-to-ten-hour elevation above, and it argues for twice-daily dosing rather than once.
What degrades it, in order. First, hydrolysis of the pyrophosphate bond in the gut wall and liver, releasing choline and cytidine. Second, cytidine deaminase, which strips the amine from cytidine to give uridine so efficiently that cytidine never reaches a measurable plasma concentration in humans — below 100 nanomolar at every dose tested Wurtman 2000. Third, ordinary intermediary metabolism: choline is oxidized to betaine or acetylated to acetylcholine or built into phospholipid, and uridine enters the pyrimidine nucleotide pool. There is no cytochrome P450 step and no meaningful renal clearance of intact drug, which is why citicoline has essentially no pharmacokinetic drug interactions.
The dosing arithmetic that follows. The community range on this card is 200 to 600 mg, which sits at or below the lowest dose Wurtman tested. At 500 mg the uridine response was already 70–90% above baseline, so a 200–600 mg dose is very likely engaging the pyrimidine arm — and going above 2 g adds nothing to it, because that arm saturates. If the effect someone is chasing is the choline arm, more helps; if it is the uridine arm, 2 g is the ceiling and the rest is expensive choline.
What would have to be true, and how you would know it was not
1. Homocysteine should fall, and nobody ever checks. Choline is oxidized to betaine, and betaine is the methyl donor for the betaine-homocysteine methyltransferase route that converts homocysteine back to methionine — the folate-independent arm of remethylation. A dose that keeps plasma choline elevated for 5 to 10 hours a day Wurtman 2000 is a real methyl-donor load. Draw homocysteine, plus RBC folate and vitamin B12 to hold the other arm constant, at baseline and at 12 weeks. Prediction: a modest fall, largest in people whose folate or B12 status is poor. This is the most directly mechanistic, cheapest and least-measured prediction on the page.
2. The prediction that cuts against it: TMAO should rise. Gut bacteria convert dietary choline to trimethylamine, which the liver oxidizes to TMAO — a metabolite repeatedly linked to cardiovascular risk. Citicoline is, among other things, a sustained choline delivery system. Nobody has ever measured TMAO on citicoline, so this is clearly labeled extrapolation, and it is the one that runs against the product: draw TMAO at baseline and 12 weeks. If it climbs, a nootropic taken for decades has a cardiovascular question attached to it that the cognitive literature has never asked.
3. Cognitive change in a healthy adult should be undetectable. The two largest randomized trials, in acute stroke and head injury, were negative Davalos 2012 Zafonte 2012, and there is no large trial in healthy people at all. So run Trail Making A and B and a MoCA at baseline and 12 weeks and expect no separation in someone whose cognition is intact. A ceiling effect is the likeliest explanation for a null result here, which is why the honest version of this prediction specifies the population: the place to look for an effect is someone with measurable impairment, not someone optimizing.
4. There is a testable dose ceiling. Plasma uridine did not rise further between 2,000 and 4,000 mg Wurtman 2000. So anybody escalating past about 2 g should see no additional benefit from the pyrimidine mechanism. If they do, either the effect is coming from the choline arm — which keeps climbing — or it is not coming from the compound.
What nobody has tested yet
Nobody has measured homocysteine in a citicoline trial. The compound has been studied for forty years, in tens of thousands of patients, and the marker most directly downstream of its own choline load has not been reported. It is on every standard panel. A hundred paired draws would answer it.
Nobody has measured TMAO on citicoline either. Same argument, opposite direction: a chronic choline donor and a metabolite with a cardiovascular literature, and no intersection between the two bodies of work. Whether the effect is trivial or not is an empirical question, and until somebody measures it the correct description is ‘unknown’ rather than ‘safe’.
Nobody has run the experiment that would justify the price. Citicoline costs several times what choline bitartrate does, and the claimed advantage is the uridine arm. The decisive trial is a three-arm comparison at equal molar choline — citicoline, choline alone, uridine alone — against the same cognitive endpoint, with plasma choline and uridine measured throughout Wurtman 2000. If choline alone matches citicoline, the premium is unjustified; if it does not, the uridine hypothesis is confirmed in the only way that matters.
And nobody has retested the population where the older literature was positive with modern methods. The negative trials were in acute stroke and acute head injury Davalos 2012 Zafonte 2012; the encouraging older data are in chronic vascular cognitive impairment Secades 2006. A properly powered, contemporary, randomized trial in that chronic population — with imaging and a validated cognitive battery — has never been run, and it is the study that would settle whether this compound has a real indication or a residual reputation.
CDP-Choline — its own safety story, not its class's
The tolerability record is genuinely excellent, and it is worth being precise about why. Citicoline is a prescription medicine in several European countries and in Japan and has been used clinically for decades; the pharmacological review of the whole record reports no serious side effects in any treated series and no significant systemic cholinergic effects Secades 2006. That second clause is the mechanistically interesting one: because the molecule is broken into two ordinary nutrients rather than acting on a receptor, it does not produce the sweating, cramping and bradycardia that a direct cholinergic agent would.
The open risk is not toxicity, it is the choline load, and it has a name. Sustained plasma choline elevation for 5 to 10 hours a day Wurtman 2000 feeds a gut bacterial pathway that produces trimethylamine, which the liver converts to TMAO. TMAO has an independent cardiovascular literature and this compound has never been tested against it. That is a mechanism-derived, clearly-labeled extrapolation rather than a reported harm — there is no signal in the clinical record — but the clinical record was mostly collected in short courses in sick people, not in healthy adults taking it daily for twenty years, and TMAO was not a recognized marker for most of it.
The other open question is what the uridine arm does over years. Uridine is the human-relevant pyrimidine here Wurtman 2000, it enters the nucleotide pool, and it has its own literature in mood and in synaptic membrane synthesis. Long-term supraphysiological pyrimidine supply is not something anyone has studied in healthy people, and the honest position is that the safety record covers the choline half far better than the uridine half.
The practical risk in the United States is regulatory rather than pharmacological. The same molecule is a licensed medicine in Europe and Japan and a dietary supplement here. The clinical safety record above was built on pharmaceutical-grade material with identity and content testing behind it; a supplement is not required to meet that standard, and the dose on the label is the claim being tested rather than a verified fact.
And the one honest efficacy warning that belongs in a safety section. The two largest randomized trials of this compound were negative Davalos 2012 Zafonte 2012. Taking a well-tolerated compound that does not work is not dangerous, but it is not free either — it displaces the intervention that would have worked.
Sources read for this page
- Wurtman RJ. Effect of oral CDP-choline on plasma choline and uridine levels in humans.. Biochem Pharmacol 2000 · PMID 10974208
- Davalos A. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).. Lancet 2012 · PMID 22691567
- Zafonte RD, Bagiella E, Ansel BM, Novack TA, Friedewald WT, Hesdorffer DC, Timmons SD, Jallo J, Eisenberg H, Hart T, Ricker JH, Diaz-Arrastia R, Merchant RE, Temkin NR, Melton S, Dikmen SS. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT).. JAMA 2012 · PMID 23168823
- Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update.. Methods Find Exp Clin Pharmacol 2006 · PMID 17171187
CDP-Choline — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This class is broad, but the predicted problems cluster by mechanism rather than by molecule. Cholinergics (racetams, and anything raising acetylcholine) predict headache — the classic one, from choline demand outrunning supply. Dopaminergics and eugeroics predict tolerance, sleep disruption and a flat mood on the days off. Anything glutamatergic or AMPA-facing carries a theoretical excitotoxicity concern at high doses.
- The pattern worth internalizing: anything that borrows performance from tomorrow eventually presents the bill. Sleep is the most common currency it gets paid in.
What has actually been reported
- Headache is the most reported effect across the racetam family and usually responds to added choline.
- Irritability, blunted affect and a rebound low on cessation are commonly reported with the stimulant-adjacent members.
- Most of this class has little or no controlled human safety data at the doses actually used.
How to reduce the risk
Same mechanism as the prediction.
- Take a choline source with any racetam. The headache is the mechanism running out of substrate, and it is largely preventable rather than something to push through.
- Dose in the morning. Almost everything in this class has a longer functional tail than its half-life suggests, and sleep is the first thing you lose.
- Use them for something, not as a habit. The compounds that carry tolerance genuinely reward intermittent use aimed at a task, and genuinely punish daily use aimed at feeling normal.
- One at a time, and long enough to judge it. This is the class where people stack five and cannot tell you which one is doing anything — and the effects are subjective, so attribution is already hard enough.
- If you need it to feel normal, stop. That is the line where a tool has become a dependency, and it is the one worth watching for.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks these. Sleep is the assay — if it is degrading, the compound is costing more than it is producing, and that shows up before anything else does.
Don't run this if
- A seizure history — several of these lower the threshold at least theoretically, and it is not worth establishing empirically.
- Bipolar disorder, for the dopaminergic members especially.
- Alongside prescribed psychiatric medication without knowing exactly how the mechanisms overlap.
The honest unknown
- Chronic use is essentially uncharacterized. The specific unmeasured thing is what daily cholinergic or dopaminergic pressure does to baseline function over years — not whether a few weeks is tolerable.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
CDP-Choline — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What CDP-Choline moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — CDP-Choline in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside CDP-Choline
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
CDP-Choline — frequently asked questions
What is CDP-Choline?
CDP-Choline (Citicoline) is a cognitive & mood research compound. Delivers choline plus cytidine/uridine — supports acetylcholine and membrane phospholipid synthesis for cognition.
Is the full CDP-Choline protocol on this page?
The reported research dose is on this page, along with how CDP-Choline works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of CDP-Choline?
CDP-Choline has an approximate half-life of Long (biphasic), which is part of what determines how often it's dosed.
What's the evidence behind CDP-Choline?
Current evidence level: Human trials. CDP-Choline is offered for research purposes only and is not an approved medicine.
CDP-Choline inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What CDP-Choline is used for
CDP-Choline appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
CDP-Choline is the cholinergic arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.